Doctors pinpoint subtle sign of deadly neurological disease that kills thousands - and it appears 15 YEARS before diagnosis
More than 150,000 people in the UK have MS, a debilitating autoimmune disease that can cause problems with sight, writing, speaking and walking as the nerves in the brain and spinal cord become permanently damaged.
People usually start to experience symptoms between the ages of 20 and 40 years.
But researchers now believe an increase in the number of GP and hospital visits linked to these issues could help flag people who are in the early stages of the disease.
A groundbreaking new study analysed the health records of over 2,000 MS patients, and tracked healthcare visits 25 years before the onset of typical symptoms.
The researches, from British Columbia, Canada, found a steady increase in the number of GP visits as early as 15 years before neurological symptoms took hold.
This included an increase in appointments related to extreme fatigue, pain, dizziness, anxiety and depression.
Whilst experts say this does not mean doctors will now be able to pinpoint if someone will go on to develop MS 15 years before the onset of neurological symptoms, the results may help doctors catch the condition earlier.
Dr Catherine Godbold, senior research communications manager at the MS society, who was not involved in the study, told the Daily Mail: 'We know that in the years leading up to an MS diagnosis, people often see their GP more and have more recorded health issues.
'Now this study has shown it may begin even earlier than we thought.
'We need more research to know which specific combination of symptoms are the most reliable early cues but the results provide valuable information to help us better understand the very early period in MS.'
Researchers say understanding what's happening in the brain and spinal cord during the prodromal stage could help diagnose the condition earlier, allowing patients to start treatment sooner and slow down the progression of the disease.
Previously, other researchers had found symptoms that appear five years before diagnosis, such as constipation, recurrent urinary tract infections (UTIs) and sexual problems.
However, because of the unpredictability of symptoms it can often take patients years to receive a diagnosis.
Whilst the precise causes of MS are still unknown, it is thought that the condition is caused by an abnormal immune response which triggers inflammation and damages the central nervous system.
Specifically, it targets the myelin sheath—the protective layer of protein and fatty acids which protects the nerves that carry signals from the brain.
While MS does not directly kill, at advanced stages, it can cause weakness in the chest muscles, leading to difficulty breathing and swallowing—which can have life-threatening complications.
Those in the late stages of the illness are also extremely vulnerable to potentially deadly infections.
The breakthrough comes following a concerning rise in cases, with around 150,000 people living with the debilitating condition in the UK.
This is up from around 130,000 in 2019, according to recent research by the MS Society.
There is currently no cure but treatments can slow the progression of the disease.
Treatment plans vary depending on the type of MS a patient has: relapsing remitting, secondary progressive or primary progressive MS.
Relapse and remitting MS involves flare-ups of symptoms where they get worse (relapse) and get better (remission).
Over time it often develops into secondary progressive MS, when symptoms are there all the time, and get slowly worse.
In the less common case of primary progressive MS, symptoms slowly getting worse over time without periods of them going away or getting better.
Treatments may include several types of medication such as steroids, disease-modifying therapies, muscle relaxants, and those to treat pain and other symptoms.
Other types of support include advice on fatigue, physiotherapy, mobility equipment, talking therapies, and cognitive rehabilitation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Physiotherapist reveals why you should NEVER cross your legs on a flight
It can be difficult to get comfortable during plane journeys, with small seats and little leg room there is often not much room for movement. Many passengers cross their legs on flights, but AXA Health physiotherapist Bethany Tomlinson has warned against the common seating position. According to research, more than one in 10 adults in the UK experience joint issues. However, this pain could be worsened by long periods of inactivity sitting on aeroplanes. Bethany explains the risks that can come with sitting cross-legged during a flight. She warns: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' Instead, the expert advises keeping legs elevated and choosing different relaxing positions. 'If there's a footrest under the seat in front of you, use this to keep your legs slightly elevated,' she adds. 'Make sure to relax your shoulders and support your back by sitting back into the plane seat whilst you wait.' To the millions of Brits jetting off this summer, Bethany urges travellers to prepare for the journey to avoid causing strain on joints. One in three Brits experience stiffness in their knees, and lack of movement or staying in the same position can only worsen this. Bethany says: 'Catching flights this summer could turn into an endurance test for our joints, so prepare for every flight like it could be long-haul. 'Knowing how to position your body and doing exercises when seated to keep your joints moving is essential.' Another way to ease joint discomfort is by standing in a certain position, Bethany explains. She adds: 'When standing up, shift weight between your feet, keep knees slightly bent and do light stretches to avoid too much pressure on your lower body.' For longer flights, Bethany shares what routine passengers should keep to in order to ensure their joints are healthy. Bethany warns passengers: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' (stock) 'Flyers need to move their body every 1-2 hours on flights to keep joints mobilised. 'Being in the same position for hours can lead to stiff and swollen joints, particularly the knees, ankles and hips. 'Seated exercises whilst in the air will help boost circulation, and reduce the risk of DVT, a common type of blood clot that can form during long periods of sitting.' The physiotherapist shared a range of mobilising exercises that passengers can easily do from their plane seat, including neck stretches, shoulder rolls and knee hugs.
The Independent
2 hours ago
- The Independent
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
The Independent
3 hours ago
- The Independent
New advanced bladder cancer treatment can ‘double chances of survival'
A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, experts say the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease. They said there had been real 'unmet need' for patients with advanced disease, with some 29 per cent of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30 per cent) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5 per cent of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
